Andrea Ruberti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Ruberti has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Xavier Freixa
Institut Clínic Cardiovascular, Clínic Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
9 shared publications- Laura Sanchis
Department of Cardiology, Cardiovascular Institute Hospital Clínic Barcelona Spain
8 shared publications - Ander Regueiro
Cardiovascular Institute, Hospital Clinic, Institut D’investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain
7 shared publications Laura Sanchis
Hospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalunya, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain; Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
6 shared publicationsEduardo Flores-Umanzor
Hospital Clínic, Cardiovascular Clinic Institute, Barcelona, Catalunya, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain; Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
5 shared publications- Giovanni Occhipinti
University of Catania
5 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19)
Clinical Outcomes and Valve Performance of Intra‐Annular Self‐Expanding Transcatheter Aortic Valve in Valve‐in‐Valve Procedures: Insights From the NAViV Registry
Background: Most evidence for transcatheter aortic valve replacement (TAVR) for valve‐in‐valve procedures comes from balloon‐expandable and supra‐annular self‐expanding valves. However, data on intra‐annular self‐expanding valves remain limited. The objectives of this registry were to evaluate the short‐ and midterm outcomes of ViV‐TAVR using the intra‐annular self‐expanding valve Navitor platform in a real‐world setting. Methods: The NAViV (Navitor Valve‐in‐Valve) registry is a retrospective, multicenter study that included 200 patients who underwent valve‐in‐valve TAVR with the Portico/Navitor systems. The primary end point was 30‐day device success. Secondary outcomes included intraprocedural technical success, early safety, and all‐cause death and major adverse events at 2 years. Results: The cohort had a high‐risk profile and a high prevalence of small surgical bioprostheses (internal diameter ≤21 mm in 86% of the patients). Technical success was achieved in 96%, with an in‐hospital mortality rate of 2% and early safety at 30 days of 84%. Mean residual gradients after TAVR were low (14 [interquartile range, 10–20] mm Hg), and residual significant aortic regurgitation was rare (1%). Device success was 73.5%, with high residual gradients (≥20 mm Hg) being the main reason for device failure. Two‐year survival and major adverse events were 85.6% and 69.8%, respectively; with low residual gradients and baseline significant AR being independently associated with higher survival. Conclusions: Valve‐in‐valve TAVR using the Portico/Navitor intra‐annular self‐expanding valve demonstrates a favorable procedural safety profile, sustained valve performance, and encouraging midterm survival in intermediate‐ and high‐risk populations. Larger and comparative studies are warranted to confirm these findings.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19)
Open AccessClinical Outcomes and Valve Performance of Intra‐Annular Self‐Expanding Transcatheter Aortic Valve in Valve‐in‐Valve Procedures: Insights From the NAViV Registry
Background: Most evidence for transcatheter aortic valve replacement (TAVR) for valve‐in‐valve procedures comes from balloon‐expandable and supra‐annular self‐expanding valves. However, data on intra‐annular self‐expanding valves remain limited. The objectives of this registry were to evaluate the short‐ and midterm outcomes of ViV‐TAVR using the intra‐annular self‐expanding valve Navitor platform in a real‐world setting. Methods: The NAViV (Navitor Valve‐in‐Valve) registry is a retrospective, multicenter study that included 200 patients who underwent valve‐in‐valve TAVR with the Portico/Navitor systems. The primary end point was 30‐day device success. Secondary outcomes included intraprocedural technical success, early safety, and all‐cause death and major adverse events at 2 years. Results: The cohort had a high‐risk profile and a high prevalence of small surgical bioprostheses (internal diameter ≤21 mm in 86% of the patients). Technical success was achieved in 96%, with an in‐hospital mortality rate of 2% and early safety at 30 days of 84%. Mean residual gradients after TAVR were low (14 [interquartile range, 10–20] mm Hg), and residual significant aortic regurgitation was rare (1%). Device success was 73.5%, with high residual gradients (≥20 mm Hg) being the main reason for device failure. Two‐year survival and major adverse events were 85.6% and 69.8%, respectively; with low residual gradients and baseline significant AR being independently associated with higher survival. Conclusions: Valve‐in‐valve TAVR using the Portico/Navitor intra‐annular self‐expanding valve demonstrates a favorable procedural safety profile, sustained valve performance, and encouraging midterm survival in intermediate‐ and high‐risk populations. Larger and comparative studies are warranted to confirm these findings.
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1639-1649
Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1639-1649
Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR
- 25 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (10) , 1313-1315
Percutaneous Annuloplasty Followed by TEER for Tricuspid Regurgitation
- 25 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (10) , 1313-1315
Percutaneous Annuloplasty Followed by TEER for Tricuspid Regurgitation
- Open Access
- 15 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3016
New-Onset Left Bundle Branch Block After TAVI: An Updated Review
Transcatheter aortic valve implantation (TAVI) has become the preferred treatment for patients with symptomatic severe aortic valve stenosis. Newer-generation devices, increased operator experience, and improved patient selection have contributed to a reduction in complication rates. However, the occurrence of new-onset left bundle branch block (LBBB) after TAVI remains high, and currently it is the most common complication associated with the procedure. This review discusses the current understanding of new-onset LBBB, including its causes, incidence, clinical outcomes, and management strategies.
- 15 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3016
Open AccessNew-Onset Left Bundle Branch Block After TAVI: An Updated Review
Transcatheter aortic valve implantation (TAVI) has become the preferred treatment for patients with symptomatic severe aortic valve stenosis. Newer-generation devices, increased operator experience, and improved patient selection have contributed to a reduction in complication rates. However, the occurrence of new-onset left bundle branch block (LBBB) after TAVI remains high, and currently it is the most common complication associated with the procedure. This review discusses the current understanding of new-onset LBBB, including its causes, incidence, clinical outcomes, and management strategies.
- Open Access
- 27 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 107649
Double LLAMACORN: Bilateral Leaflet Modification Technique to Prevent Coronary Obstruction
- 27 March 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 107649
Open AccessDouble LLAMACORN: Bilateral Leaflet Modification Technique to Prevent Coronary Obstruction
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (3) , e015984
Transcatheter Mitral and Aortic Paravalvular Leak Closure: Innovations, Challenges, and Future Directions
Paravalvular leak (PVL) is a well-known complication of valve replacement, occurring in up to 10% of aortic and 17% of mitral prosthetic valves. Although many leaks are small and clinically insignificant, ≈1% to 5% of cases are associated with clinically relevant complications, such as heart failure symptoms and hemolytic anemia. Surgical reoperation is currently considered the first-line option; however, it encompasses high mortality and morbidity risks. In the past years, transcatheter PVL closure has proven to be highly effective when performed in experienced centers. Transcatheter PVL closure requires advanced imaging modalities, specialized materials, and techniques, reflecting the high complexity of the procedure. We review the complex nature of PVL, including its diagnostic workup and the available transcatheter treatment strategies, with a special focus on the treatment of mitral and aortic PVL using plugging devices.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (3) , e015984
Transcatheter Mitral and Aortic Paravalvular Leak Closure: Innovations, Challenges, and Future Directions
Paravalvular leak (PVL) is a well-known complication of valve replacement, occurring in up to 10% of aortic and 17% of mitral prosthetic valves. Although many leaks are small and clinically insignificant, ≈1% to 5% of cases are associated with clinically relevant complications, such as heart failure symptoms and hemolytic anemia. Surgical reoperation is currently considered the first-line option; however, it encompasses high mortality and morbidity risks. In the past years, transcatheter PVL closure has proven to be highly effective when performed in experienced centers. Transcatheter PVL closure requires advanced imaging modalities, specialized materials, and techniques, reflecting the high complexity of the procedure. We review the complex nature of PVL, including its diagnostic workup and the available transcatheter treatment strategies, with a special focus on the treatment of mitral and aortic PVL using plugging devices.
- Open Access
- 23 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (1)
Measurement of turbulent kinetic energy with colour Doppler echocardiography and particle tracing velocimetry in an ex-vivo aortic stenosis model
Introduction: Grading of aortic stenosis (AS) is paramount to determine the ideal timing for aortic valve replacement. However, echocardiographic assessment of AS is challenging and subject to inaccuracy. Increased turbulent kinetic energy (TKE) in the aorta, created by a restricted opening stenotic aortic valve, could serve as a new marker for assessing AS severity. However, in this contest, TKE evaluated with ultrasound colour Doppler have not yet been clinically validated. Methods and results: Porcine aortic valves were tested ex-vivo in a left heart mock loop under various flowrates (1, 2.5, and 4 L/min) and three stiffness grades (SGa, SGb, SGc as native, stiffer, and stiffest stiffness grade, respectively). Reference TKE values were obtained using backlight particle tracking velocimetry. In parallel, TKE was estimated from ultrasound colour Doppler measurements by computing the local spatial fluctuations of blood flow velocities. Transvalvular pressure gradients were evaluated both with continuous wave Doppler and pressure sensors (PGaolv). At 4 L/min, pressure gradients with continuous wave Doppler for SGc reached severe AS levels (41 mmHg ± 14). Both TKE measurement methods, adjusted for flow rates, increased significantly across all stiffness grades and distinguished between severe (SGc) and non-severe (SGa and SGb) AS. Conclusion: In this ex-vivo AS model, both TKE measurement methods successfully differentiated severe from non-severe AS. These findings underscore the potential importance of ultrasound colour Doppler echocardiography in estimating energy loss through turbulence, paving the way for the development of a new diagnostic tool for grading AS severity.
- 23 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (1)
Open AccessMeasurement of turbulent kinetic energy with colour Doppler echocardiography and particle tracing velocimetry in an ex-vivo aortic stenosis model
Introduction: Grading of aortic stenosis (AS) is paramount to determine the ideal timing for aortic valve replacement. However, echocardiographic assessment of AS is challenging and subject to inaccuracy. Increased turbulent kinetic energy (TKE) in the aorta, created by a restricted opening stenotic aortic valve, could serve as a new marker for assessing AS severity. However, in this contest, TKE evaluated with ultrasound colour Doppler have not yet been clinically validated. Methods and results: Porcine aortic valves were tested ex-vivo in a left heart mock loop under various flowrates (1, 2.5, and 4 L/min) and three stiffness grades (SGa, SGb, SGc as native, stiffer, and stiffest stiffness grade, respectively). Reference TKE values were obtained using backlight particle tracking velocimetry. In parallel, TKE was estimated from ultrasound colour Doppler measurements by computing the local spatial fluctuations of blood flow velocities. Transvalvular pressure gradients were evaluated both with continuous wave Doppler and pressure sensors (PGaolv). At 4 L/min, pressure gradients with continuous wave Doppler for SGc reached severe AS levels (41 mmHg ± 14). Both TKE measurement methods, adjusted for flow rates, increased significantly across all stiffness grades and distinguished between severe (SGc) and non-severe (SGa and SGb) AS. Conclusion: In this ex-vivo AS model, both TKE measurement methods successfully differentiated severe from non-severe AS. These findings underscore the potential importance of ultrasound colour Doppler echocardiography in estimating energy loss through turbulence, paving the way for the development of a new diagnostic tool for grading AS severity.
- 15 December 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (4) , 916-924
Impact of Preprocedural Anemia on Outcomes in Patients With Tricuspid Regurgitation Undergoing Transcatheter Edge‐to‐Edge Repair: Insights From the TRISPA Registry
Background: Tricuspid transcatheter edge‐to‐edge repair (T‐TEER) is an established treatment for tricuspid regurgitation (TR) in patients at high surgical risk. Although anemia is a well‐established predictor of poor outcomes in other transcatheter valvular interventions, its role in the tricuspid field remains poorly characterized. Aims: To evaluate the clinical impact of anemia in a cohort of patients undergoing T‐TEER. Methods: A total of 487 patients undergoing T‐TEER at 15 centers between 2020 and 2025 were included. Anemia was defined as a hemoglobin level < 13 g/dL in men and < 12 g/dL in women. The primary outcome was the composite of all‐cause mortality and heart failure hospitalization (HFH) at 2‐year follow‐up, with each component also evaluated separately as secondary outcomes. Results: Anemia was present in 174 patients (35.7%). Compared to those without anemia, patients with baseline anemia had a higher burden of baseline comorbidities, as well as more frequent right ventricular remodeling and tricuspid annular dilatation. Rates of in‐hospital clinical complications were similar between groups ( p = 0.696), but patients with anemia had higher rates of residual TR ≥ 3+ ( p = 0.038). The composite endpoint at 2 years (49% vs. 12%, p < 0.001), as well as all‐cause mortality (26% vs. 9%) and HFH (31% vs. 13%), were significantly higher in anemic patients. In the multivariate analysis, anemia was an independent predictor of all‐cause mortality at follow‐up (hazard ratio 3.03 [1.30–7.96]; p = 0.01). Conclusions: Baseline anemia is common among patients undergoing T‐TEER and is associated with increased mortality and higher TR residual degree.
- 15 December 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (4) , 916-924
Impact of Preprocedural Anemia on Outcomes in Patients With Tricuspid Regurgitation Undergoing Transcatheter Edge‐to‐Edge Repair: Insights From the TRISPA Registry
Background: Tricuspid transcatheter edge‐to‐edge repair (T‐TEER) is an established treatment for tricuspid regurgitation (TR) in patients at high surgical risk. Although anemia is a well‐established predictor of poor outcomes in other transcatheter valvular interventions, its role in the tricuspid field remains poorly characterized. Aims: To evaluate the clinical impact of anemia in a cohort of patients undergoing T‐TEER. Methods: A total of 487 patients undergoing T‐TEER at 15 centers between 2020 and 2025 were included. Anemia was defined as a hemoglobin level < 13 g/dL in men and < 12 g/dL in women. The primary outcome was the composite of all‐cause mortality and heart failure hospitalization (HFH) at 2‐year follow‐up, with each component also evaluated separately as secondary outcomes. Results: Anemia was present in 174 patients (35.7%). Compared to those without anemia, patients with baseline anemia had a higher burden of baseline comorbidities, as well as more frequent right ventricular remodeling and tricuspid annular dilatation. Rates of in‐hospital clinical complications were similar between groups ( p = 0.696), but patients with anemia had higher rates of residual TR ≥ 3+ ( p = 0.038). The composite endpoint at 2 years (49% vs. 12%, p < 0.001), as well as all‐cause mortality (26% vs. 9%) and HFH (31% vs. 13%), were significantly higher in anemic patients. In the multivariate analysis, anemia was an independent predictor of all‐cause mortality at follow‐up (hazard ratio 3.03 [1.30–7.96]; p = 0.01). Conclusions: Baseline anemia is common among patients undergoing T‐TEER and is associated with increased mortality and higher TR residual degree.
- Open Access
- 7 November 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (11) , 440
Pharmacological and Interventional Prevention and Treatment of Microvascular Obstruction Following Primary PCI in STEMI
Microvascular obstruction (MVO) accounts for up to 50% of patients diagnosed with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The pathogenesis is multifactorial and includes myocardial ischemia, distal embolization, and ischemia–reperfusion injury, in a context of individual susceptibility. Its occurrence has been related to adverse outcomes. Despite an extensive body of research, no single pharmacological or interventional strategy has proven effectiveness. The inconclusive nature of the evidence can be attributed to lack of standardization among studies in terms of drugs used and their dosage, the variability in study designs, and the fact that available studies performed a decade ago feature reperfusion strategies and drugs used that differ significantly from the current standard of care. In this context, our review aims to discuss the pharmacological and interventional approaches to MVO.
- 7 November 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (11) , 440
Open AccessPharmacological and Interventional Prevention and Treatment of Microvascular Obstruction Following Primary PCI in STEMI
Microvascular obstruction (MVO) accounts for up to 50% of patients diagnosed with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The pathogenesis is multifactorial and includes myocardial ischemia, distal embolization, and ischemia–reperfusion injury, in a context of individual susceptibility. Its occurrence has been related to adverse outcomes. Despite an extensive body of research, no single pharmacological or interventional strategy has proven effectiveness. The inconclusive nature of the evidence can be attributed to lack of standardization among studies in terms of drugs used and their dosage, the variability in study designs, and the fact that available studies performed a decade ago feature reperfusion strategies and drugs used that differ significantly from the current standard of care. In this context, our review aims to discuss the pharmacological and interventional approaches to MVO.
- Open Access
- 1 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (30) , 105280
Percutaneous Orthotopic Transcatheter Tricuspid Valve Replacement for Native Valve Destruction After Endocarditis
- 1 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (30) , 105280
Open AccessPercutaneous Orthotopic Transcatheter Tricuspid Valve Replacement for Native Valve Destruction After Endocarditis